AN OPEN LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF ODEVIXIBAT (A4250) IN PATIENTS WITH ALAGILLE SYNDROME

Registry ID

A4250-015

Source registry

HEALTH_CANADA

Status

Closed

Study type

INTERVENTIONAL

Sponsor

ALBIREO AB

Completion date

2022-07-05

Last update

2021-08-26

Conditions

• ALAGILLE SYNDROME

Related clinical trials

• A MULTICENTER EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND DURABILITY OF THE THERAPEUTIC EFFECT OF LUM001, AN APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITOR (ASBTI), IN THE TREATMENT OF CHOLESTATIC LIVER DISEASE IN PEDIATRIC SUBJECTS WITH ALAGILLE SYNDROME

View on source registry